IL‐6 inhibition with ziltivekimab (an IL‐6 ligand inhibition)8, 9 and canakinumab [an interleukin‐1β (IL‐1β) ligand inhibition]10 disrupted multiple atherogenic inflammatory pathways and inhibited atherosclerosis. This evidence concerns the gene IL6 and atherosclerosis.